Drug intelligence / Profile preview

VaxiFlu-S

Development stage: Unknown
Lead developer: Zydus Lifesciences
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**VaxiFlu-S** is a Zydus inactivated, whole-virion, monovalent influenza A(H1N1)pdm09 vaccine developed for active immunization against pandemic H1N1 influenza. The official Indian product information identifies each 0.5 mL dose as containing 15 micrograms of hemagglutinin antigen from the egg-derived, beta-propiolactone-inactivated A/California/7/2009 H1N1 NIBRG-121xp strain. It is administered by intramuscular injection, preferably into the deltoid, and was indicated for adults aged 18 years and older.

Brand names: VaxiFlu-S

Beyond the preview

Go deeper on VaxiFlu-S.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VaxiFlu-S.

Explore the full profile